Business highlights in Q1 2024
- In January the company announced that the company will expand to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications
- In January the company announced the decision to to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a directed buyback of shares in order to sell shares to the board of directors under the LTI2021-program
- In February the company announced the decision to carry out a capital increase directed at MAC Clinical Research Finance Ltd (“MAC”) in connection with MAC’s conversion notice regarding conversion of outstanding receivable on February 20th
Business highlights after this reporting period
- Nothing to report.
Financial Highlights
| First Quarter (2024-01-01 – 2024-03-31) |
| · Net revenue were KDKK 0 (0) |
| · Operating loss, EBIT was KDKK -3,577 (-8,677) |
| · Earnings per share before and after dilution was DKK -0.08 (-0.18) |
| · Cash: KDKK 18,760 (24,336) |
| · Solidity: 97% (37%) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/